Previous 10 | Next 10 |
2023-11-23 23:58:43 ET Summary Amylyx Pharmaceuticals shows impressive revenue growth post-Relyvrio launch, yet faces competition in the ALS treatment market. Financially strong with minimal cash burn and high current ratio; operational challenges like high Relyvrio discontinuatio...
2023-11-21 09:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the 6th Annual Evercore ISI HealthCONx Conference. The conference is being conducted in-person in Miami, Fl...
The law firm of Kirby McInerney LLP is investigating potential claims against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX ). The investigation concerns whether Amylyx and/or certain of its officers have violated the federal securities...
NEW YORK, NY / ACCESSWIRE / November 13, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities are encouraged to obtain additiona...
2023-11-11 12:39:10 ET Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2023 Earnings Conference Call November 09, 2023 08:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations & Communications Josh Cohen - Co-CEO & Co-Founder Justin Klee - Co-CE...
2023-11-09 10:00:37 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
2023-11-09 07:38:28 ET More on Amylyx Pharmaceuticals Amylyx Pharmaceuticals: A High Risk/High Reward Stock Amylyx Achieves Profitability On Wings Of Relyvrio (Rating Upgrade) Seeking Alpha’s Quant Rating on Amylyx Pharmaceuticals Historical earnings d...
Third quarter 2023 product revenue of $102.7 million; bringing total product revenue to $272.3 million in the first three full quarters of U.S. launch Strong financial position supported by $20.9 million of net income during the third quarter of 2023 and cash, cash equivalents and short-t...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...